Most Community-Based Oncologists Skip Biomarker Testing
A recent survey shows that fewer than half of community oncologists use biomarker testing to guide patient discussions about treatment,
Read moreA recent survey shows that fewer than half of community oncologists use biomarker testing to guide patient discussions about treatment,
Read more(Reuters Health) – Despite adjustments to the U.S. Preventive Services Task Force lung cancer screening criteria, disparities in eligibility between
Read moreA single-arm, phase 2 clinical trial of atezolizumab with chemotherapy for patients with nonsquamous non-small cell lung cancer (NSCLC) and
Read moreNew data on the use of immunotherapy in early stages of non–small cell lung cancer (NSCLC) have sparked a debate
Read moreNEW YORK (Reuters Health) – Adding veliparib to platinum-based chemotherapy for first-line treatment of current smokers with advanced squamous non-small-cell
Read moreCancer death rates in the United States continue to decline overall for many common cancers. This decline is particularly prounounced
Read moreThe US Food and Drug Administration (FDA) today granted an accelerated approval for amivantamab (Rybrevant) as the first targeted treatment
Read moreFeb. 17, 2021 — Rush Limbaugh, for decades a popular, controversial, and influential talk radio host and conservative commentator, cheap
Read more